118 , 569588 (2021) Mehrotra, P.: Biosensors and their applicationsa review
doi: 10.1177/2050640614520867 Gusev EI, Skvortsova VI, Dambinova SA, Raevskiy KS, Alekseev AA, Bashkatova VG, et al
Major insurers across the country have cut coverage: Blue Cross Blue Shield affiliates in Michigan, Massachusetts, and other states ended coverage for Wegovy, Zepbound, and Saxenda for weight loss effective January 2025 and January 2026
Providers may recommend Rybelsus for patients unwilling to try injectables, while reserving Ozempic or Wegovy (injectable semaglutide for obesity) for those needing higher efficacy